科睿唯安：2026最值得关注的肿瘤药物预测报告：ASCO 关键启示（英文版）（24页）.pdf

1、Oncology Drugs to Watch Top takeaways from ASCO 2026Contents03 Introduction04 Methodology and contributors06 Key ASCO 2026 takeaways 07 Perioperative Erleada improves pathological response and MFS in high-risk localized prostate cancer08 Adjuvant Retevmo improves EFS in resectable RET-positive NSCLC

2、09 STRIDE-based combinations challenge TACE alone in unresectable eeHCC10 TALAPRO-3 strengthens the PARP inhibitor paradigm in HRR-mutatedmHSPC11 PersevERA misses primary PFS endpoint in first-line ER-positive/HER2-negative metastatic breast cancer12 Switching to camizestrant at emergent ESR1 mutati

3、on significantly improves PFS2 in first-line HR-positive/HER2-negative breast cancer13 Incytes Monjuvi/Minjuvi+R2-CHOP extends PFS in frontline DLBCL14 Mezigdomide in combination with Kyprolis and dexamethasonesignificantly improves PFS in relapsed or refractory multiple myeloma15 Daraxonrasib shows

4、 unprecedented OS benefit in previously treatedmetastatic pancreatic ductal adenocarcinoma16 Rybrevant Faspro demonstrates pivotal efficacy in later-line HPVunrelated recurrent or metastatic SCCHN 17 Key ASCO takeaways from Mainland China18 Yidafang plus chemotherapy demonstrates OS superiority over

5、 PD-1 backbone in first-line squamous NSCLC19 Zegfrovy outperforms chemotherapy in first-line EGFR exon20insNSCLC20 References 4IntroductionNew targets,maturing modalities and hope for hard-to-treat cancers at ASCO 2026doubled survival in patients with both RAS-mutant and RAS-wild-type metastatic pa

6、ncreatic ductal adenocarcinoma(mPDAC),with fewer side effects than chemotherapy,the current standard of care.That read-out,which drew a standing ovation from attendees,represented a huge leap forward in the treatment of a notoriously difficult-to-treat cancer and,as BioWorld notes,it was not the onl